Current studies Contact Details Country overview Filter Options Quick Search Filter Options Conditions Activated PI3K delta Syndrome (APDS)Active Ankylosing SpondylitisActive Psoriatic ArthritisAdvanced solid tumorsAlzheimer’s DiseaseAnkylosing SpondylitisAnterior Uveitis (AU)Atopic dermatitisAxial SpondyloarthrithisAxial SpondyloarthritisAxial Spondyloarthritis (axSpA)CDKL5 Deficiency DisorderChildhood absence epilepsyChronic Allograft InjuryChronic inflammatory demyelinating polyradiculoneuropathy (CIDP)Chronic Plaque PsoriasisCrohn's DiseaseDravet SyndromeDrug-resistant EpilepsyEarly-stage parkinson's diseaseElectroencephalographic neonatal seizuresEpilepsyEpilepsy with partial onset seizures or generalized tonic-clonic seizuresEpilepsy with partial-onset seizuresFibromyalgiaFocal-Onset SeizuresGeneralized Myasthenia GravisGeneralized Myasthenia Gravis TESTGeneralized pustular psoriasis and erythrodermic psoriasisHealthy ParticipantsHealthy Study ParticipantsHealthy VolunteersHidradenitis SuppurativaHighly drug-resistant focal epilepsyImmune Mediated Necrotizing MyopathyJuvenile absence epilepsyLennox Gastaut SyndromeLeucine-Rich Glioma Inactivated 1 Autoimmune EncephalitisMixed guttate/plaque psoriasisModerate and severe active Rheumatoid ArthritisModerate chronic plaque psoriasisModerate to Severe Chronic Plaque PsoriasisModerate to Severe Plaque PsoriasisModerate to severe PsoriasisModerately to severely active Crohn's DiseaseMyasthenia GravisMyasthenia Gravis, GeneralizedMyelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)Nonradiographic Axial Spondyloarthritisnr-axSpAOsteoporosisParkinson DiseaseParkinson's DiseaseParkinson’s diseaseParoxysmal Nocturnal Hemoglobinuria (PNH)Partial SeizuresPartial seizures with or without secondary generalizationPartial-onset SeizuresPlaque PsoriasisPolyarticular-course Juvenile Idiopathic Arthritis (JIA)Primary Immune ThrombocytopeniaProgressive Supranuclear PalsyPsoriasisPsoriatic Arthritisr-axSpaRestless Legs SyndromeRheumatoid ArthritisSevere Active Ulcerative ColitisSevere chronic plaque psoriasisStereotypical prolonged seizuresSystemic lupus erythematosusSystemic Lupus Erythematosus (SLE)ThrombocytopeniaThymidine Kinase 2 (TK2) DeficiencyThymidine Kinase 2 Deficiency Studies That Include Woman Man All Studies Incorporating These Age Groups 0-17 18-65 66+ All ages Product Name Bepranemab Bimekizumab Bimzelx® Brivaracetam Briviact® Certolizumab pegol Cimzia® Dapirolizumab pegol EVENITY Fintepla Ginisortamab Keppra® Lacosamide Levetiracetam Neupro® RA101495 Romosozumab Rotigotine Rozanolixizumab RYSTIGGO Staccato Alprazolam UCB0022 UCB0107 UCB0599 UCB1381 UCB6114 UCB7665 UCB7853 UCB7858 UCB9741 Vimpat® Zampilimab ZILBRYSQ® Zilucoplan Status Recruiting Not yet recruiting Enrolling by invitation Active, not recruiting Study Title Minimum Age Maximum age Studies That Include Status A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures 12 Years - All Recruiting A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures Stereotypical prolonged seizures Learn More A Multicenter Open-Label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Activity of Zilucoplan in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis 12 Years 17 Years All Recruiting A Multicenter Open-Label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Activity of Zilucoplan in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis Generalized Myasthenia Gravis Learn More A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Examine The Efficacy And Safety Of ZX008 In Subjects With CDKL5 Deficiency Disorder Followed By An Open-Label Extension 1 Years 35 Years All Recruiting A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Examine The Efficacy And Safety Of ZX008 In Subjects With CDKL5 Deficiency Disorder Followed By An Open-Label Extension CDKL5 Deficiency Disorder Learn More A Multicenter Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease 35 Years 85 Years All Recruiting A Multicenter Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease Parkinson Disease Learn More Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome 1 Years 23 Months All Recruiting Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome Dravet Syndrome Learn More An open-label, single-arm study evaluating the activity, safety, and pharmacokinetics of rozanolixizumab in pediatric study participants with moderate to severe generalized myasthenia gravis 2 Years 17 Years All Recruiting An open-label, single-arm study evaluating the activity, safety, and pharmacokinetics of rozanolixizumab in pediatric study participants with moderate to severe generalized myasthenia gravis Generalized Myasthenia Gravis Learn More A Multicenter, Randomized, Parallel-Group, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents from 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis 6 Years 17 Years All Recruiting A Multicenter, Randomized, Parallel-Group, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents from 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis Moderate to Severe Plaque Psoriasis Learn More A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) 18 Years 65 Years All Recruiting A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) Atopic dermatitis Learn More A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD) 18 Years 89 Years All Recruiting A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD) Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD) Learn More A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2 Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy 2 Years 25 Years All Recruiting A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2 Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Childhood absence epilepsy Learn More A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE LONG-TERM SAFETY AND TOLERABILITY OF BRIVARACETAM IN STUDY PARTICIPANTS WITH CHILDHOOD ABSENCE EPILEPSY OR JUVENILE ABSENCE EPILEPSY 2 Years - All Recruiting A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE LONG-TERM SAFETY AND TOLERABILITY OF BRIVARACETAM IN STUDY PARTICIPANTS WITH CHILDHOOD ABSENCE EPILEPSY OR JUVENILE ABSENCE EPILEPSY Childhood absence epilepsy Learn More A Multicenter, Open-Label, Randomized, Active Comparator Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures - 28 Days All Recruiting A Multicenter, Open-Label, Randomized, Active Comparator Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures Electroencephalographic neonatal seizures Learn More A Multicenter, Open-Label, Outpatient Study to Evaluate the Safe And Effective Use of a Zilucoplan Auto-Injector Combination Product for Subcutaneous Self-Administration by Study Participants with Generalized Myasthenia Gravis 18 Years - All Recruiting A Multicenter, Open-Label, Outpatient Study to Evaluate the Safe And Effective Use of a Zilucoplan Auto-Injector Combination Product for Subcutaneous Self-Administration by Study Participants with Generalized Myasthenia Gravis Generalized Myasthenia Gravis Learn More Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO) 6 Years 17 Years All Recruiting Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO) Moderate chronic plaque psoriasis Learn More A SINGLE CENTER, RANDOMIZED, INVESTIGATOR- AND PARTICIPANT-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, ETHNOBRIDGING PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PHARMACOKINETICS AFTER SINGLE-DOSE OF UCB9741 IN HEALTHY CAUCASIAN AND JAPANESE PARTICIPANTS 18 Years 55 Years All Recruiting A SINGLE CENTER, RANDOMIZED, INVESTIGATOR- AND PARTICIPANT-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, ETHNOBRIDGING PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PHARMACOKINETICS AFTER SINGLE-DOSE OF UCB9741 IN HEALTHY CAUCASIAN AND JAPANESE PARTICIPANTS Healthy Participants Learn More An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Zilucoplan in Pediatric Study Participants With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis 12 Years - All Not yet recruiting An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Zilucoplan in Pediatric Study Participants With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis Generalized Myasthenia Gravis Learn More A Phase 3b Exploratory Multicenter Open-Label Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis 18 Years - All Not yet recruiting A Phase 3b Exploratory Multicenter Open-Label Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis Moderate to Severe Plaque Psoriasis Learn More An open-label Extension study to evaluate rozanolixizumab in pediatric study participants with generalized myasthenia gravis 12 Years - All Not yet recruiting An open-label Extension study to evaluate rozanolixizumab in pediatric study participants with generalized myasthenia gravis Generalized Myasthenia Gravis Learn More An Open-Label, Randomized Study to Evaluate the Relative Bioavailability of a New Tablet Formulation of Minzasolmin and the Potential Effect of Food on the Pharmacokinetics of Minzasolmin in Healthy Participants 18 Years 55 Years All Not yet recruiting An Open-Label, Randomized Study to Evaluate the Relative Bioavailability of a New Tablet Formulation of Minzasolmin and the Potential Effect of Food on the Pharmacokinetics of Minzasolmin in Healthy Participants Healthy Participants Learn More A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis 18 Years - All Not yet recruiting A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis Psoriatic Arthritis Learn More A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus 16 Years - All Enrolling by invitation A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus Systemic lupus erythematosus Learn More An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures 12 Years - All Enrolling by invitation An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures Stereotypical prolonged seizures Learn More A Multicenter, Open-Label, Single-Arm Study to Evaluate Long-Term Safety, Tolerability, and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy 2 Years 26 Years All Enrolling by invitation A Multicenter, Open-Label, Single-Arm Study to Evaluate Long-Term Safety, Tolerability, and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy Childhood absence epilepsy Learn More An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects >=16 Years of Age with Partial Seizures With or Without Secondary Generalization 16 Years - All Enrolling by invitation An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects >=16 Years of Age with Partial Seizures With or Without Secondary Generalization Partial seizures with or without secondary generalization Learn More A Multicenter, Noninterventional, Prospective Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Moderate to Severe Plaque Psoriasis in Daily Practice 18 Years - All Active, not recruiting A Multicenter, Noninterventional, Prospective Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Moderate to Severe Plaque Psoriasis in Daily Practice Plaque Psoriasis Learn More Load More
